表紙:PEG化タンパク質の市場規模、シェア、動向分析レポートタンパク質タイプ別(CSF、インターフェロン)、用途別(がん、肝炎)、製品・サービス別(消耗品、サービス)、エンドユーザー別、およびセグメント別予測、2022年~2030年
市場調査レポート
商品コード
1147620

PEG化タンパク質の市場規模、シェア、動向分析レポートタンパク質タイプ別(CSF、インターフェロン)、用途別(がん、肝炎)、製品・サービス別(消耗品、サービス)、エンドユーザー別、およびセグメント別予測、2022年~2030年

PEGylated Proteins Market Size, Share & Trends Analysis Report By Protein Type (CSF, Interferons), By Application (Cancer, Hepatitis), By Product & Services (Consumables, Services), By End-user, And Segment Forecasts, 2022 - 2030

出版日: | 発行: Grand View Research | ページ情報: 英文 200 Pages | 納期: 2~10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=152.41円
PEG化タンパク質の市場規模、シェア、動向分析レポートタンパク質タイプ別(CSF、インターフェロン)、用途別(がん、肝炎)、製品・サービス別(消耗品、サービス)、エンドユーザー別、およびセグメント別予測、2022年~2030年
出版日: 2022年10月31日
発行: Grand View Research
ページ情報: 英文 200 Pages
納期: 2~10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

PEG化タンパク質の市場成長と動向

Grand View Research, Inc.の新しいレポートによると、世界のPEG化タンパク質市場規模は、予測期間中に11.71%のCAGRを記録し、2030年までに30億6000万米ドルに達すると予想されています。PEG化は、治療薬、薬剤、ベシクルなどの分子にポリエチレングリコールポリマー鎖を共有および非共有結合で結合させるプロセスです。PEG化化合物には、タンパク質分解防止機能の向上、半減期の延長、低毒性、低免疫原性など、業界拡大に寄与するその他の特典も備わっています。

一方、PEG化プロセスのコスト上昇と一部の医薬品の特許切れにより、業界の拡大がある程度抑制されると予想されます。しかし、非タンパク質ベースの薬剤よりもタンパク質ベースの薬剤を好む傾向が強まっており、PEG化によってタンパク質の安定性と循環半減期が改善されるため、予測期間中にPEG化タンパク質産業の成長を促進すると予想されます。がん、腎臓病、関節リウマチのような慢性疾患の発生率が上昇していることが、産業拡大の主な要因となっています。例えば、IARC(国際がん研究機関)は、2020年の世界におけるがん死亡者数は1030万人、新たながん患者数は1930万人と推定しています。

さらに、年間2950万人の新規発症のうち、2040年までに1640万人ががんに関連した原因で死亡すると予測されています。また、国連合同エイズ計画(UNAIDS)のファクトシート「Global HIV and AIDS Statistics 2021」によると、2020年にHIV陽性と診断された人は世界で3770万人に上ります。その結果、世界中の慢性&感染症の負担とともに、医薬品を製造する需要が高まることが予想されます。このことは、研究を促進し、業界の成長を後押しすることになるでしょう。COVID-19は業界にプラスの影響を与えたと予想されます。

2021年6月に発表された「PEGylated nanoparticle albumin-bound steroidal ginsenoside derivatives alleviate SARS-CoV-2-mediated hyper-inflammatory responses」と題する研究によると、SARS-CoV-2 ICU患者で、PEGylated Nano Particle Albumin-Bound(PNAB)-steroidal GinsenosideはヒストンH4とNETosis関連因子の血漿レベルを下げることが成功し、SREBP2媒介全身炎症を軽減させることができるといいます。PNAB-ステロイドジンセノサイド薬は、重症のSARS-CoV-2患者によく見られる凝固とサイトカインストームの症状を治療するのに役立つと思われます。したがって、COVID-19のパンデミックは、PEG化技術を使用して行われたかなりの研究活動を考えると、業界に好影響を与えました。

さらに、製薬会社やバイオテクノロジー企業による研究開発プロジェクトへの投資の増加も、業界の拡大を後押ししています。例えば、2022年3月、抗体特性評価やタンパク質精製プロジェクトを強化・迅速化するために設立されたプロテインサイエンス部門のFlow Eighteen38の親会社であるCRO FairJourneyBiologics S.Aは、同部門のタンパク質生産と物理・生物特性評価能力およびサービスに対して500万ユーロ(558万米ドル)の投資を発表しています。このような投資は、市場全体の成長を補うと予想されます。また、ここ数年、主要プレイヤーが研究開発プロジェクトを支援するために戦略的パートナーシップを結ぶなど、業界再編の傾向が顕著に見られます。

例えば、2022年2月、Merck KGaAは、脂質ナノ粒子(LNP)ベースのドラッグデリバリー技術を取り入れたPEG化医薬品と複雑な注射剤に焦点を当てたバイオ医薬品CDMOであるExeleadを買収しました。さらに、2022年7月には、欧州医薬品庁(EMA)のヒト用医薬品委員会(CHMP)において、ドキソルビシン塩酸塩(Celdoxome pegylated liposomal)が、進行卵巣がん、転移性乳がん、AIDS関連カポジ肉腫、進行多発骨髄腫の治癒を目的として承認勧告されました。このように、業界の成長を促進しています。

PEG化蛋白質市場レポートハイライト

キットベースのPEG化製品ラインの利用が拡大しているため、消耗品製品・サービスセグメントが2021年に最大のシェアを占めた

2021年にはコロニー刺激因子タンパク質型セグメントがより大きなシェアを占めました。コロニー刺激因子は、血球の発達を促進し、その機能を向上させるため、がん治療中の人の免疫力を高めるのに役立つ。

したがって、腫瘍学におけるコロニー刺激因子の広範な使用は、このセグメントの成長を促進するでしょう。

世界のがんの発生率の高さとがんに対するペプチド治療の利用により、がんの応用分野は2021年に大きなシェアを占めました。

製薬・バイオテクノロジー企業のエンドユーザーセグメントが2021年に最も大きなシェアを占めた

バイオテクノロジーおよび製薬企業によるPEG化タンパク質に対する研究開発費の増加が、セグメントの成長をさらに押し上げるだろう

モノクローナル抗体、エリスロポエチン、インターフェロンなどの慢性疾患の治療のための生物学的薬剤の高い使用、政府資金、研究活動のための資金、PEG化タンパク質の進行中のプロジェクトの上昇により、2021年に北米が最大の地域となった

アジア太平洋地域は、対象疾患の増加およびPEG化タンパク質の高い採用率により、予測期間中、最も高いCAGRで成長すると予想されます。

目次

第1章 調査手法と範囲

  • 調査手法
  • 調査の仮定
  • 調査手法
  • 情報調達
    • 購入したデータベース
    • Gvrの内部データベース
    • 二次情報
    • 1次調査
  • 情報またはデータ分析
    • データ分析モデル
  • 市場の策定と検証
  • モデルの詳細
    • コモディティフロー分析
      • アプローチ1:コモディティフローアプローチ
      • アプローチ2:ボトムアップアプローチを使用した国ごとの市場予測
  • 世界市場:CAGR計算
  • 二次情報一覧
  • 一次情報のリスト
  • 目的

第2章 エグゼクティブサマリー

  • 市場スナップショット、2021年

第3章 市場変数、動向、範囲

  • 市場セグメンテーションと範囲
  • 市場力学
    • 市場促進要因分析
      • タンパク質ベースの医薬品の採用の増加
      • 治療用タンパク質のペグ化の利点
      • 生物製剤の研究開発費の増加
    • 市場抑制要因分析
      • PEG化の生産プロセスのコストが高い
      • 新規ペグ化生物製剤の特許満了
  • 浸透と成長の見通しマッピング、2021年
  • COVID-19影響分析
  • PEG化タンパク質市場分析ツール
    • SWOT分析、要因別(政治と法律、経済、技術)
    • ポーターのファイブフォース分析

第4章 製品とサービスのビジネス分析

  • PEG化タンパク質市場:製品およびサービスの変動分析
  • 消耗品
  • サービス

第5章 タンパク質タイプのビジネス分析

  • PEG化タンパク質市場:タンパク質タイプの変動分析
  • コロニー刺激因子
  • インターフェロン
  • エリスロポエチン
  • 組換え第VII因子
  • その他

第6章 アプリケーションビジネス分析

  • PEG化タンパク質市場:アプリケーションの変動分析
  • がん
  • 自己免疫疾患
  • 肝炎
  • 多発性硬化症
  • 血友病
  • 胃腸障害
  • その他

第7章 エンドユーザーのビジネス分析

  • PEG化タンパク質市場:エンドユーザーの変動分析
  • 製薬およびバイオテクノロジー企業
  • 受託調査機関
  • 学術・調査機関

第8章 地域ビジネス分析

  • PEG化タンパク質市場:地域変動分析
  • 北米
    • 米国
    • カナダ
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
  • アジア太平洋地域
    • 日本
    • 中国
    • インド
    • オーストラリア
    • 韓国
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • アルゼンチン
  • 中東とアフリカ
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦

第9章 競合情勢

  • 戦略的枠組み
  • 企業プロファイル
    • THERMO FISHER SCIENTIFIC, INC.
      • 会社概要
      • 財務実績
      • 製品のベンチマーク
      • 戦略的イニシアチブ
    • ABCAM PLC
      • 会社概要
      • 財務実績
      • 製品のベンチマーク
      • 戦略的イニシアチブ
    • ENZON PHARMACEUTICALS, INC.
      • 会社概要
      • 財務実績
      • 製品のベンチマーク
      • 戦略的イニシアチブ
    • MERCK KGAA
      • 会社概要
      • 財務実績
      • 製品のベンチマーク
      • 戦略的イニシアチブ
    • CELARES GMBH
      • 会社概要
      • 財務実績
      • 製品のベンチマーク
      • 戦略的イニシアチブ
    • PROFACGEN
      • 会社概要
      • 財務実績
      • 製品のベンチマーク
      • 戦略的イニシアチブ
    • CREATIVE PEGWORKS
      • 会社概要
      • 財務実績
      • 製品のベンチマーク
      • 戦略的イニシアチブ
    • NOF CORPORATION
      • 会社概要
      • NOFアメリカ株式会社
      • 財務実績
      • 製品のベンチマーク
      • 戦略的イニシアチブ
    • AURIGENE PHARMACEUTICAL SERVICES LTD.
      • 会社概要
      • 財務実績
      • 製品のベンチマーク
      • 戦略的イニシアチブ
    • LAYSAN BIO, INC.
      • 会社概要
      • 財務実績
      • 製品のベンチマーク
      • 戦略的イニシアチブ
図表

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global PEGylated Proteins Market, by Product & Services, 2018 - 2030 (USD Million)
  • Table 4 Global PEGylated Proteins Market, by Protein Type, 2018 - 2030 (USD Million)
  • Table 5 Global PEGylated Proteins Market, by Application, 2018 - 2030 (USD Million)
  • Table 6 Global PEGylated Proteins Market, by End - user, 2018 - 2030 (USD Million)
  • Table 7 Global PEGylated Proteins Market, by Region, 2018 - 2030 (USD Million)
  • Table 8 North America PEGylated Proteins Market, by Country, 2018 - 2030 (USD Million)
  • Table 9 North America PEGylated Proteins Market, by Product & Services, 2018 - 2030 (USD Million)
  • Table 10 North America PEGylated Proteins Market, by Protein Type, 2018 - 2030 (USD Million)
  • Table 11 North America PEGylated Proteins Market, Application, 2018 - 2030 (USD Million)
  • Table 12 North America PEGylated Proteins Market, End - user, 2018 - 2030 (USD Million)
  • Table 13 U.S. PEGylated Proteins Market, by Product & Services, 2018 - 2030 (USD Million)
  • Table 14 U.S. PEGylated Proteins Market, by Protein Type, 2018 - 2030 (USD Million)
  • Table 15 U.S. PEGylated Proteins Market, by Application, 2018 - 2030 (USD Million)
  • Table 16 U.S. PEGylated Proteins Market, by End - user, 2018 - 2030 (USD Million)
  • Table 17 Canada PEGylated Proteins Market, by Product & Services, 2018 - 2030 (USD Million)
  • Table 18 Canada PEGylated Proteins Market, by Protein Type, 2018 - 2030 (USD Million)
  • Table 19 Canada PEGylated Proteins Market, by Application, 2018 - 2030 (USD Million)
  • Table 20 Canada PEGylated Proteins Market, by End - user, 2018 - 2030 (USD Million)
  • Table 21 Europe PEGylated Proteins Market, by Country, 2018 - 2030 (USD Million)
  • Table 22 Europe PEGylated Proteins Market, by Product & Services, 2018 - 2030 (USD Million)
  • Table 23 Europe PEGylated Proteins Market, by Protein Type, 2018 - 2030 (USD Million)
  • Table 24 Europe PEGylated Proteins Market, by Application, 2018 - 2030 (USD Million)
  • Table 25 Europe PEGylated Proteins Market, by End - user, 2018 - 2030 (USD Million)
  • Table 26 Germany PEGylated Proteins Market, by Product & Services, 2018 - 2030 (USD Million)
  • Table 27 Germany PEGylated Proteins Market, by Protein Type, 2018 - 2030 (USD Million)
  • Table 28 Germany PEGylated Proteins Market, by Application, 2018 - 2030 (USD Million)
  • Table 29 Germany PEGylated Proteins Market, by End - user, 2018 - 2030 (USD Million)
  • Table 30 U.K. PEGylated Proteins Market, by Product & Services, 2018 - 2030 (USD Million)
  • Table 31 U.K. PEGylated Proteins Market, by Protein Type, 2018 - 2030 (USD Million)
  • Table 32 U.K. PEGylated Proteins Market, by Application, 2018 - 2030 (USD Million)
  • Table 33 U.K. PEGylated Proteins Market, by End - user, 2018 - 2030 (USD Million)
  • Table 34 France PEGylated Proteins Market, by Product & Services, 2018 - 2030 (USD Million)
  • Table 35 France PEGylated Proteins Market, by Protein Type, 2018 - 2030 (USD Million)
  • Table 36 France PEGylated Proteins Market, by Application, 2018 - 2030 (USD Million)
  • Table 37 France PEGylated Proteins Market, by End - user, 2018 - 2030 (USD Million)
  • Table 38 Italy PEGylated Proteins Market, by Product & Services, 2018 - 2030 (USD Million)
  • Table 39 Italy PEGylated Proteins Market, by Protein Type, 2018 - 2030 (USD Million)
  • Table 40 Italy PEGylated Proteins Market, by Application, 2018 - 2030 (USD Million)
  • Table 41 Italy PEGylated Proteins Market, by End - user, 2018 - 2030 (USD Million)
  • Table 42 Spain PEGylated Proteins Market, by Product & Services, 2018 - 2030 (USD Million)
  • Table 43 Spain PEGylated Proteins Market, by Protein Type, 2018 - 2030 (USD Million)
  • Table 44 Spain PEGylated Proteins Market, by Application, 2018 - 2030 (USD Million)
  • Table 45 Spain PEGylated Proteins Market, by End - user, 2018 - 2030 (USD Million)
  • Table 46 Asia Pacific PEGylated Proteins Market, by Country, 2018 - 2030 (USD Million)
  • Table 47 Asia Pacific PEGylated Proteins Market, by Product & Services, 2018 - 2030 (USD Million)
  • Table 48 Asia Pacific PEGylated Proteins Market, by Protein Type, 2018 - 2030 (USD Million)
  • Table 49 Asia Pacific PEGylated Proteins Market, by Application, 2018 - 2030 (USD Million)
  • Table 50 Asia Pacific PEGylated Proteins Market, by End - user, 2018 - 2030 (USD Million)
  • Table 51 China PEGylated Proteins Market, by Product & Services, 2018 - 2030 (USD Million)
  • Table 52 China PEGylated Proteins Market, by Protein Type, 2018 - 2030 (USD Million)
  • Table 53 China PEGylated Proteins Market, by Application, 2018 - 2030 (USD Million)
  • Table 54 China PEGylated Proteins Market, by End - user, 2018 - 2030 (USD Million)
  • Table 55 Japan PEGylated Proteins Market, by Product & Services, 2018 - 2030 (USD Million)
  • Table 56 Japan PEGylated Proteins Market, by Protein Type, 2018 - 2030 (USD Million)
  • Table 57 Japan PEGylated Proteins Market, by Application, 2018 - 2030 (USD Million)
  • Table 58 Japan PEGylated Proteins Market, by End - user, 2018 - 2030 (USD Million)
  • Table 59 India PEGylated Proteins Market, by Product & Services, 2018 - 2030 (USD Million)
  • Table 60 India PEGylated Proteins Market, by Protein Type, 2018 - 2030 (USD Million)
  • Table 61 India PEGylated Proteins Market, by Application, 2018 - 2030 (USD Million)
  • Table 62 India PEGylated Proteins Market, by End - user, 2018 - 2030 (USD Million)
  • Table 63 South Korea PEGylated Proteins Market, by Product & Services, 2018 - 2030 (USD Million)
  • Table 64 South Korea PEGylated Proteins Market, by Protein Type, 2018 - 2030 (USD Million)
  • Table 65 South Korea PEGylated Proteins Market, by Application, 2018 - 2030 (USD Million)
  • Table 66 South Korea PEGylated Proteins Market, by End - user, 2018 - 2030 (USD Million)
  • Table 67 Australia PEGylated Proteins Market, by Product & Services, 2018 - 2030 (USD Million)
  • Table 68 Australia PEGylated Proteins Market, by Protein Type, 2018 - 2030 (USD Million)
  • Table 69 Australia PEGylated Proteins Market, by Application, 2018 - 2030 (USD Million)
  • Table 70 Australia PEGylated Proteins Market, by End - user, 2018 - 2030 (USD Million)
  • Table 71 Latin America PEGylated Proteins Market, by Country, 2018 - 2030 (USD Million)
  • Table 72 Latin America PEGylated Proteins Market, by Product & Services, 2018 - 2030 (USD Million)
  • Table 73 Latin America PEGylated Proteins Market, by Protein Type, 2018 - 2030 (USD Million)
  • Table 74 Latin America PEGylated Proteins Market, by Application, 2018 - 2030 (USD Million)
  • Table 75 Latin America PEGylated Proteins Market, by End - user, 2018 - 2030 (USD Million)
  • Table 76 Brazil PEGylated Proteins Market, by Product & Services, 2018 - 2030 (USD Million)
  • Table 77 Brazil PEGylated Proteins Market, by Protein Type, 2018 - 2030 (USD Million)
  • Table 78 Brazil PEGylated Proteins Market, by Application, 2018 - 2030 (USD Million)
  • Table 79 Brazil PEGylated Proteins Market, by End - user, 2018 - 2030 (USD Million)
  • Table 80 Mexico PEGylated Proteins Market, by Product & Services, 2018 - 2030 (USD Million)
  • Table 81 Mexico PEGylated Proteins Market, by Protein Type, 2018 - 2030 (USD Million)
  • Table 82 Mexico PEGylated Proteins Market, by Application, 2018 - 2030 (USD Million)
  • Table 83 Mexico PEGylated Proteins Market, by End - user, 2018 - 2030 (USD Million)
  • Table 84 Argentina PEGylated Proteins Market, by Product & Services, 2018 - 2030 (USD Million)
  • Table 85 Argentina PEGylated Proteins Market, by Protein Type, 2018 - 2030 (USD Million)
  • Table 86 Argentina PEGylated Proteins Market, by Application, 2018 - 2030 (USD Million)
  • Table 87 Argentina PEGylated Proteins Market, by End - user, 2018 - 2030 (USD Million)
  • Table 88 Middle East & Africa PEGylated Proteins Market, by Country, 2018 - 2030 (USD Million)
  • Table 89 Middle East & Africa PEGylated Proteins Market, by Product & Services, 2018 - 2030 (USD Million)
  • Table 90 Middle East & Africa PEGylated Proteins Market, by Protein Type, 2018 - 2030 (USD Million)
  • Table 91 Middle East & Africa PEGylated Proteins Market, by Application, 2018 - 2030 (USD Million)
  • Table 92 Middle East & Africa PEGylated Proteins Market, by End - user, 2018 - 2030 (USD Million)
  • Table 93 South Africa PEGylated Proteins Market, by Product & Services, 2018 - 2030 (USD Million)
  • Table 94 South Africa PEGylated Proteins Market, by Protein Type, 2018 - 2030 (USD Million)
  • Table 95 South Africa PEGylated Proteins Market, by Application, 2018 - 2030 (USD Million)
  • Table 96 South Africa PEGylated Proteins Market, by End - user, 2018 - 2030 (USD Million)
  • Table 97 Saudi Arabia PEGylated Proteins Market, by Product & Services, 2018 - 2030 (USD Million)
  • Table 98 Saudi Arabia PEGylated Proteins Market, by Protein Type, 2018 - 2030 (USD Million)
  • Table 99 Saudi Arabia PEGylated Proteins Market, by Application, 2018 - 2030 (USD Million)
  • Table 100 Saudi Arabia PEGylated Proteins Market, by End - user, 2018 - 2030 (USD Million)
  • Table 101 UAE PEGylated Proteins Market, by Product & Services, 2018 - 2030 (USD Million)
  • Table 102 UAE PEGylated Proteins Market, by Protein Type, 2018 - 2030 (USD Million)
  • Table 103 UAE PEGylated Proteins Market, by Application, 2018 - 2030 (USD Million)
  • Table 104 UAE PEGylated Proteins Market, by End - user, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information Procurement
  • Fig. 3 Primary Research Pattern
  • Fig. 4 Market Research Approaches
  • Fig. 5 Value Chain - Based Sizing & Forecasting
  • Fig. 6 Market Formulation & Validation
  • Fig. 7 PEGylated Proteins, Market Segmentation
  • Fig. 8 Market Snapshot, 2021
  • Fig. 9 Market Trends & Outlook
  • Fig. 10 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 11 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 12 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • Fig. 13 Porter's Five Forces Analysis
  • Fig. 14 Market Penetration Vs Growth Prospect Mapping, 2021
  • Fig. 15 Global PEGylated Proteins Market, Product & Services Outlook: Key Takeaways
  • Fig. 16 Global PEGylated Proteins Market: Product & Services Movement Analysis
  • Fig. 17 Global PEGylated Proteins Market, for Consumables, 2018 - 2030 (USD Million)
  • Fig. 18 Global PEGylated Proteins Market, for Services, 2018 - 2030 (USD Million)
  • Fig. 19 Global PEGylated Proteins Market, Protein Type Outlook: Key Takeaways
  • Fig. 20 Global PEGylated Proteins Market: Protein Type Movement Analysis
  • Fig. 21 Global PEGylated Proteins Market, for Colony - stimulating factor, 2018 - 2030 (USD Million)
  • Fig. 22 Global PEGylated Proteins Market, for Interferons, 2018 - 2030 (USD Million)
  • Fig. 23 Global PEGylated Proteins Market, for Erythropoietin, 2018 - 2030 (USD Million)
  • Fig. 24 Global PEGylated Proteins Market, for Recombinant factor VII, 2018 - 2030 (USD Million)
  • Fig. 25 Global PEGylated Proteins Market, for Others, 2018 - 2030 (USD Million)
  • Fig. 26 Global PEGylated Proteins Market, Application Outlook: Key Takeaways
  • Fig. 27 Global PEGylated Proteins Market: Application Movement Analysis
  • Fig. 28 Global PEGylated Proteins Market, for Cancer, 2018 - 2030 (USD Million)
  • Fig. 29 Global PEGylated Proteins Market, for Autoimmune diseases, 2018 - 2030 (USD Million)
  • Fig. 30 Global PEGylated Proteins Market, for Hepatitis, 2018 - 2030 (USD Million)
  • Fig. 31 Global PEGylated Proteins Market, for Multiple sclerosis, 2018 - 2030 (USD Million)
  • Fig. 32 Global PEGylated Proteins Market, for Hemophilia, 2018 - 2030 (USD Million)
  • Fig. 33 Global PEGylated Proteins Market, for Gastrointestinal disorders, 2018 - 2030 (USD Million)
  • Fig. 34 Global PEGylated Proteins Market, for Others, 2018 - 2030 (USD Million)
  • Fig. 35 Global PEGylated Proteins Market, End - user Outlook: Key Takeaways
  • Fig. 36 Global PEGylated Proteins Market: End - user Movement Analysis
  • Fig. 37 Global PEGylated Proteins Market, for Pharmaceutical & biotechnology companies, 2018 - 2030 (USD Million)
  • Fig. 38 Global PEGylated Proteins Market, for Contract research organizations, 2018 - 2030 (USD Million)
  • Fig. 39 Global PEGylated Proteins Market, for Academic & research institutes, 2018 - 2030 (USD Million)
  • Fig. 40 Regional Marketplace: Key Takeaways
  • Fig. 41 Global PEGylated Proteins Market: Regional Movement Analysis
  • Fig. 42 North America PEGylated Proteins Market, 2018 - 2030 (USD Million)
  • Fig. 43 U.S. PEGylated Proteins Market, 2018 - 2030 (USD Million)
  • Fig. 44 Canada PEGylated Proteins Market, 2018 - 2030 (USD Million)
  • Fig. 45 Europe PEGylated Proteins Market, 2018 - 2030 (USD Million)
  • Fig. 46 Germany PEGylated Proteins Market, 2018 - 2030 (USD Million)
  • Fig. 47 U.K. PEGylated Proteins Market, 2018 - 2030 (USD Million)
  • Fig. 48 France PEGylated Proteins Market, 2018 - 2030 (USD Million)
  • Fig. 49 Italy PEGylated Proteins Market, 2018 - 2030 (USD Million)
  • Fig. 50 Spain PEGylated Proteins Market, 2018 - 2030 (USD Million)
  • Fig. 51 Asia Pacific PEGylated Proteins Market, 2018 - 2030 (USD Million)
  • Fig. 52 Japan PEGylated Proteins Market, 2018 - 2030 (USD Million)
  • Fig. 53 China PEGylated Proteins Market, 2018 - 2030 (USD Million)
  • Fig. 54 India PEGylated Proteins Market, 2018 - 2030 (USD Million)
  • Fig. 55 Australia PEGylated Proteins Market, 2018 - 2030 (USD Million)
  • Fig. 56 South Korea PEGylated Proteins Market, 2018 - 2030 (USD Million)
  • Fig. 57 Latin America PEGylated Proteins Market, 2018 - 2030 (USD Million)
  • Fig. 58 Brazil PEGylated Proteins Market, 2018 - 2030 (USD Million)
  • Fig. 59 Mexico PEGylated Proteins Market, 2018 - 2030 (USD Million)
  • Fig. 60 Argentina PEGylated Proteins Market, 2018 - 2030 (USD Million)
  • Fig. 61 Middle East and Africa PEGylated Proteins Market, 2018 - 2030 (USD Million)
  • Fig. 62 South Africa PEGylated Proteins Market, 2018 - 2030 (USD Million)
  • Fig. 63 Saudi Arabia PEGylated Proteins Market, 2018 - 2030 (USD Million)
  • Fig. 64 UAE PEGylated Proteins Market, 2018 - 2030 (USD Million)
目次
Product Code: GVR-4-68039-990-1

PEGylated Proteins Market Growth & Trends:

The global PEGylated proteins market size is expected to reach USD 3.06 billion by 2030, registering a CAGR of 11.71% over the forecast period, according to a new report by Grand View Research, Inc. PEGylation is the process of attaching polyethylene glycol polymer chains to molecules, such as therapeutics, medication, or vesicle, covalently & non-covalently. The industry is anticipated to grow significantly over the projected period, primarily as a result of the rising demand for PEGylation, an increase in the prevalence of chronic diseases, and the existence of potent new treatment candidates.PEGylated compounds also have certain additional benefits that contribute to the industry expansion, including increased proteolytic protection, a longer half-life, lower toxicity, and lower immunogenicity.

On the other hand, increased PEGylation process costs and the patent expiration of some medications are anticipated to restrain industry expansion to some extent. However, the growing preference for protein-based medications over non-protein-based drugs and the improvement of protein stability and circulation half-life by PEGylation is expected to propel the PEGylated protein industry growth in the forecast period. The rising incidence of chronic diseases like cancer, kidney disease, and rheumatoid arthritis is the main factor contributing to the industry's expansion. For instance, the IARC (International Agency for Research on Cancer) estimates that there were 10.3 million cancer deaths and 19.3 million new cases of cancer worldwide in 2020.

Furthermore, 16.4 million people are expected to die from cancer-related causes by 2040, out of an estimated 29.5 million new instances of the disease per year. In addition, 37.7 million people worldwide were diagnosed HIV positive in 2020, according to the Global HIV and AIDS Statistics 2021 fact sheet from the Joint United Nations Program on HIV/AIDS (UNAIDS). As a result, the demand for producing medicines is anticipated to rise along with the burden of chronic & infectious diseases across the globe. This will encourage research and propel the industry's growth. It is anticipated that COVID-19 had a positive effect on the industry.

According to a study titled "PEGylated nanoparticle albumin-bound steroidal ginsenoside derivatives alleviate SARS-CoV-2-mediated hyper-inflammatory responses," published in June 2021, in SARS-CoV-2 ICU patients, PEGylated Nanoparticle Albumin-Bound (PNAB)-steroidal Ginsenoside can successfully reduce plasma levels of histone H4 and NETosis-related factors and reduce SREBP2-mediated systemic inflammation. PNAB-steroidal ginsenoside drugs may help treat coagulation and cytokine storm symptoms that are common in severe SARS-CoV-2 patients. Therefore, the COVID-19 pandemic had a favorable impact on the industry given the considerable research activities conducted using PEGylation technology.

In addition, the industry expansion is being boosted by the rising investments made in R&D projects by pharmaceutical and biotechnology firms. For instance, in March 2022, CRO FairJourneyBiologics S.A., the parent company of Flow Eighteen38, a division of protein sciences, established to enhance and expedite antibody characterization as well as protein purification projects, announced an investment of EUR 5 million (USD 5.58 million) into the division's protein production and physical and biological characterization capabilities and services. Such investments are anticipated to supplement the overall market growth. In addition, there is a discernible trend toward industry consolidation over the past years, with key players forming strategic partnerships to support the R&D projects.

For instance, in February 2022, Merck KGaA acquired Exelead, a biopharmaceutical CDMO with a focus on PEGylated pharmaceuticals and intricate injectable formulations, incorporating Lipid Nanoparticle (LNP)-based drug delivery technology. Furthermore, in July 2022, the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP), Doxorubicin hydrochloride (Celdoxome pegylated liposomal) was recommended for approval for the cure of advanced ovarian cancer, metastatic breast cancer, AIDS-related Kaposi's sarcoma, and progressing multiple myeloma. Thus, propelling the industry's growth.

PEGylated Proteins Market Report Highlights:

  • The consumables product & service segment accounted for the largest share in 2021 due to the growing usage of kit-based PEGylation product lines
  • The colony-stimulating factor protein type segment held a larger share in 2021. Colony-stimulating chemicals speed up the development of blood cells and improve their functionality, therefore they help boost a person's immune system while they are receiving cancer treatment
  • Thus, extensive use of colony-stimulating factors in oncology will promote the growth of this segment
  • The cancer application segment held a larger share in 2021 due to the high incidence of cancer worldwide and the use of peptide therapy for cancer
  • The pharmaceutical & biotechnology companies end-user segment held the largest share in 2021
  • The rising R&D expenditure by biotechnology and pharmaceutical firms for PEGylated protein will further boost the segment growth
  • North America was the largest region in 2021 due to the high use of biological medications for the treatment of chronic diseases, such as monoclonal antibodies, erythropoietin, and interferon, as well as rising government funding, funding for research activities, and ongoing projects for PEGylated protein
  • Asia Pacific is expected to grow at the highest CAGRover the forecast period due to the rising prevalence of target diseases and high PEGylated protein adoption

Table of Contents

Chapter 1 Methodology And Scope

  • 1.1 Research Methodology
  • 1.2 Research Assumptions
    • 1.2.1 Estimates And Forecast Timeline
  • 1.3 Research Methodology
  • 1.4 Information Procurement
    • 1.4.1 Purchased Database
    • 1.4.2 Gvr's Internal Database
    • 1.4.3 Secondary Sources
    • 1.4.4 Primary Research
  • 1.5 Information Or Data Analysis
    • 1.5.1 Data Analysis Models
  • 1.6 Market Formulation & Validation
  • 1.7 Model Details
    • 1.7.1 Commodity Flow Analysis
      • 1.7.1.1 Approach 1: Commodity Flow Approach
      • 1.7.1.2 Approach 2: Country Wise Market Estimation Using Bottom Up Approach
  • 1.8 Global Market: CAGR Calculation
  • 1.9 List of Secondary Sources
  • 1.10 List of Primary Sources
  • 1.11 Objectives
    • 1.11.1 Objective 1:
    • 1.11.2 Objective 2:

Chapter 2 Executive Summary

  • 2.1 Market Snapshot, 2021

Chapter 3 Market Variables, Trends & Scope

  • 3.1 Market Segmentation & Scope
  • 3.2 Market Dynamics
    • 3.2.1 Market Drivers Analysis
      • 3.2.1.1 Increasing Adoption Of Proteins Based Drugs
      • 3.2.1.2 Advantages Of Pegylation Of Therapeutic Proteins
      • 3.2.1.3 Increased Spending On R&D Of Biologics
    • 3.2.2 Market Restraint Analysis
      • 3.2.2.1 High cost of production process for PEGylation
      • 3.2.2.2 Patent expiration for novel PEGylated biologics
  • 3.3 Penetration and Growth Prospect Mapping, 2021
  • 3.4 COVID - 19 Impact Analysis
  • 3.5 PEGylated Proteins Market Analysis Tools
    • 3.5.1 Swot Analysis, By Factor (Political & Legal, Economic, And Technological)
    • 3.5.2 Porter's Five Forces Analysis

Chapter 4 Product & Services Business Analysis

  • 4.1 Pegylated Proteins Market: Product & Services Movement Analysis
  • 4.2 Consumables
    • 4.2.1 Global Pegylated Proteins Market For Consumables Estimates And Forecast, 2018 - 2030 (USD Million)
  • 4.3 Services
    • 4.3.1 Global Pegylated Proteins Market For Services Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 5 Protein Type Business Analysis

  • 5.1 PEGylated Proteins Market: Protein Type Movement Analysis
  • 5.2 Colony - stimulating factor
    • 5.2.1 Global Pegylated Proteins Market For Colony - Stimulating Factor Estimates And Forecast, 2018 - 2030 (USD Million)
  • 5.3 Interferons
    • 5.3.1 Global Pegylated Proteins Market For Interferons Estimates And Forecast, 2018 - 2030 (USD Million)
  • 5.4 Erythropoietin
    • 5.4.1 Global Pegylated Proteins Market For Erythropoietin Estimates And Forecast, 2018 - 2030 (USD Million)
  • 5.5 Recombinant Factor Vii
    • 5.5.1 Global Pegylated Proteins Market For Recombinant Factor Vii Estimates And Forecast, 2018 - 2030 (USD Million)
  • 5.6 Others
    • 5.6.1 Global Pegylated Proteins Market For Other Proteins Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 6 Application Business Analysis

  • 6.1 Pegylated Proteins Market: Application Movement Analysis
  • 6.2 Cancer
    • 6.2.1 Global Pegylated Proteins Market For Cancer Estimates And Forecast, 2018 - 2030
  • 6.3 Autoimmune Diseases
    • 6.3.1 Global Pegylated Proteins Market For Autoimmune Diseases Estimates And Forecast, 2018 - 2030
  • 6.4 Hepatitis
    • 6.4.1 Global Pegylated Proteins Market For Hepatitis Estimates And Forecast, 2018 - 2030
  • 6.5 Multiple Sclerosis
    • 6.5.1 Global Pegylated Proteins Market For Multiple Sclerosis Estimates And Forecast, 2018 - 2030
  • 6.6 Hemophilia
    • 6.6.1 Global Pegylated Proteins Market For Hemophilia Estimates And Forecast, 2018 - 2030
  • 6.7 Gastrointestinal Disorders
    • 6.7.1 Global Pegylated Proteins Market For Gastrointestinal Disorders Estimates And Forecast, 2018 - 2030
  • 6.8 Others
    • 6.8.1 Global Pegylated Proteins Market For Other Applications Estimates And Forecast, 2018 - 2030

Chapter 7 End - user Business Analysis

  • 7.1 PEGylated Proteins Market: End - user Movement Analysis
  • 7.2 Pharmaceutical & Biotechnology Companies
    • 7.2.1 Global Pegylated Proteins Market For Pharmaceutical & Biotechnology Companies Estimates And Forecast, 2018 - 2030 (USD Million)
  • 7.3 Contract Research Organizations
    • 7.3.1 Global Pegylated Proteins Market For Contract Research Organizations Estimates And Forecast, 2018 - 2030 (USD Million)
  • 7.4 Academic & Research Institutes
    • 7.4.1 Global Pegylated Proteins Market For Academic & Research Institutes Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 8 Regional Business Analysis

  • 8.1 PEGylated Proteins Market: Regional Movement Analysis
  • 8.2 North America
    • 8.2.1 North America Pegylated Proteins Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 8.2.2 U.S.
      • 8.2.2.1 U.S. Pegylated Proteins Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 8.2.3 Canada
      • 8.2.3.1 Canada Pegylated Proteins Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 8.3 Europe
    • 8.3.1 Europe Pegylated Proteins Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 8.3.2 Germany
      • 8.3.2.1 Germany Pegylated Proteins Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 8.3.3 France
      • 8.3.3.1 France Pegylated Proteins Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 8.3.4 U.K.
      • 8.3.4.1 U.K. Pegylated Proteins Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 8.3.5 Italy
      • 8.3.5.1 Italy Pegylated Proteins Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 8.3.6 Spain
      • 8.3.6.1 Spain Pegylated Proteins Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 8.4 Asia - Pacific
    • 8.4.1 Asia - Pacific Pegylated Proteins Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 8.4.2 Japan
      • 8.4.2.1 Japan Pegylated Proteins Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 8.4.3 China
      • 8.4.3.1 China Pegylated Proteins Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 8.4.4 India
      • 8.4.4.1 India Pegylated Proteins Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 8.4.5 Australia
      • 8.4.5.1 Australia Pegylated Proteins Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 8.4.6 South Korea
      • 8.4.6.1 South Korea Pegylated Proteins Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 8.5 Latin America
    • 8.5.1 Latin America Pegylated Proteins Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 8.5.2 Brazil
      • 8.5.2.1 Brazil Pegylated Proteins Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 8.5.3 Mexico
      • 8.5.3.1 Mexico Pegylated Proteins Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 8.5.4 Argentina
      • 8.5.4.1 Argentina Pegylated Proteins Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 8.6 Middle East And Africa
    • 8.6.1 Middle - East And Africa Pegylated Proteins Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 8.6.2 South Africa
      • 8.6.2.1 South Africa Pegylated Proteins Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 8.6.3 Saudi Arabia
      • 8.6.3.1 Saudi Arabia PEGylated Proteins market estimates and forecast, 2018 - 2030 (USD Million)
    • 8.6.4 UAE
      • 8.6.4.1 UAE PEGylated Proteins market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 9 COMPETITIVE LANDSCAPE

  • 9.1 Strategy Framework
  • 9.2 Company Profiles
    • 9.2.1 THERMO FISHER SCIENTIFIC, INC.
      • 9.2.1.1 Company overview
      • 9.2.1.2 Financial performance
      • 9.2.1.3 Product benchmarking
      • 9.2.1.4 Strategic initiatives
    • 9.2.2 ABCAM PLC
      • 9.2.2.1 Company overview
      • 9.2.2.2 Financial performance
      • 9.2.2.3 Product benchmarking
      • 9.2.2.4 Strategic initiatives
    • 9.2.3 ENZON PHARMACEUTICALS, INC.
      • 9.2.3.1 Company overview
      • 9.2.3.2 Financial performance
      • 9.2.3.3 Product benchmarking
      • 9.2.3.4 Strategic initiatives
    • 9.2.4 MERCK KGAA
      • 9.2.4.1 Company overview
      • 9.2.4.2 Financial performance
      • 9.2.4.3 Product benchmarking
      • 9.2.4.4 Strategic initiatives
    • 9.2.5 CELARES GMBH
      • 9.2.5.1 Company overview
      • 9.2.5.2 Financial performance
      • 9.2.5.3 Product benchmarking
      • 9.2.5.4 Strategic initiatives
    • 9.2.6 PROFACGEN
      • 9.2.6.1 Company overview
      • 9.2.6.2 Financial performance
      • 9.2.6.3 Product benchmarking
      • 9.2.6.4 Strategic initiatives
    • 9.2.7 CREATIVE PEGWORKS
      • 9.2.7.1 Company overview
      • 9.2.7.2 Financial performance
      • 9.2.7.3 Product benchmarking
      • 9.2.7.4 Strategic initiatives
    • 9.2.8 NOF CORPORATION
      • 9.2.8.1 Company overview
      • 9.2.8.1.1 NOF AMERICA CORPORATION
      • 9.2.8.2 Financial performance
      • 9.2.8.3 Product benchmarking
      • 9.2.8.4 Strategic initiatives
    • 9.2.9 AURIGENE PHARMACEUTICAL SERVICES LTD.
      • 9.2.9.1 Company overview
      • 9.2.9.2 Financial performance
      • 9.2.9.3 Product benchmarking
      • 9.2.9.4 Strategic initiatives
    • 9.2.10 LAYSAN BIO, INC.
      • 9.2.10.1 Company overview
      • 9.2.10.2 Financial performance
      • 9.2.10.3 Product benchmarking
      • 9.2.10.4 Strategic initiatives